演題詳細

一般口演 / Oral Session

一般口演 8 (Oral Session 8) :MDS:臨床 2

print

日程
2013年10月11日(金)
時間
10:30 - 11:30
会場
第6会場 / Room No.6 (ロイトン札幌 2F エンプレス)
座長・司会
前田 嘉信 (Yoshinobu Maeda):1
1:岡山大学病院 血液・腫瘍・呼吸器・アレルギー内科
 
前へ戻る

Retrospective analysis of allogeneic HSCT for MDS : A single institution experience

演題番号 : OS-1-38

川瀬 有美 (Yumi Kawase):1、近藤 忠一 (Tadakazu Kondo):1、前田 猛 (Takeshi Maeda):1、河原 真大 (Masahiro Kawahara):1、北脇 年雄 (Toshio Kitawaki):1、北野 俊行 (Toshiyuki Kitano):1、山下 浩平 (Kouhei Yamashita):1、川端 浩 (Hiroshi Kawabata):1、門脇 則光 (Norimitsu Kadowaki):1、高折 晃史 (Akifumi Takaori-Kondo):1

1:Department of Hematology and Oncology, Kyoto Univ., Japan

 

[Background]Allo-SCT is the only curative treatment of MDS. It is important to assess risk factors to improve transplant outcomes. [Patients and methods]We retrospectively analyzed 42 patients with MDS (excluding overt-AML) treated with allo-SCT in our institution from January 2000 to December 2012. [Results]Median age was 56yo.(range,27-67). Diagnosis(FAB-classification) included RA (n=7), RAEB (n=28), RAEB-t (n=6) and unknown (n=1). Pre-transplant treatments were induction chemotherapies in 21, azacitidine in 4, and neither in 17. Disease statuses at SCT were CR (n=8), refractory (n=12), relapse (n=5) and untreated (n=17). Karyotypes according to IPSS were good (n=15), intermediate (n=8) and poor (n=17). Conditioning regimens were myeloablative (n=19) and reduced intensity (n=23). The stem cell sources were BM (n=28), PB (n=4) and CB (n=10). There were gradeII-IV aGVHD in 16 patients, gradeIII-IV in 4 and cGVHD in 17. With a median follow-up after SCT of 542 days (range,15-4565), 5-year overall survival was 47.5%. Eighteen patients died of PD (n=1), relapse (n=6) or complications of SCT (n=11; VOD in 1, GVHD in 3, infection in 3, non-infectious pneumonia in 2, and others in 2). By univariate analysis, age>=50yo., intermediate/poor-risk karyotypes, BM blasts>=5% at the time of SCT were associated with poor transplant outcomes, while the stem cell sources and conditioning regimens were not. [Conclusions]Our study suggested that age, BM blasts and karyotypes at the time of SCT were associated with survival and also decreasing post-SCT complications could improve SCT outcome.

前へ戻る